Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1614 1628
This examiner grants 42% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19540128 | INHIBITORS OF RIPK2 AND MEDICAL USES THEREOF | Final Rejection | Odyssey Therapeutics, Inc. |
| 17779015 | PRODRUGS OF FULVESTRANT | Non-Final OA | KASHIV BIOSCIENCES, LLC |
| 17628794 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 AND USES THEREOF | Final Rejection | Dana-Farber Cancer Institute, Inc. |
| 18008750 | REJUVENATION OF AGED TISSUES BY INHIBITION OF THE PGE2 DEGRADING ENZYME, 15-PGDH | Final Rejection | The Board of Trustees of the Leland Stanford Junior University |
| 18007308 | THERAPEUTIC USES OF GLUCOCORTICOIDS WITH ANABOLIC EFFECTS IN SKELETAL MUSCLE | Final Rejection | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED |
| 18434367 | MODULATION OF SEX STEROID HORMONE PRODUCTION AND ACTIVITY FOR TREATING AND PREVENTING HERNIAS | Non-Final OA | Northwestern University |
| 17996343 | STABLE DIGLYCERIDE EMULSIONS AND METHODS FOR TREATING ORGAN INJURY | Non-Final OA | The Trustees of Columbia University in the City of New York |
| 18835261 | USE OF RETINOIDS FOR TREATMENT OF ATRIAL FIBRILLATION | Non-Final OA | NEW YORK UNIVERSITY |
| 18002572 | ORAL LIQUID FORMULATIONS OF RUXOLITINIB | Non-Final OA | Novartis AG |
| 17313938 | METHOD OF PERSONALIZED TREATMENT FOR CARDIOMYOPATHY AND HEART FAILURE AND OTHER RELATED DISEASES BY MEASURING RENIN ACTIVITY, PRO-RENIN, PRO-RENIN RECEPTOR LEVELS IN BLOOD | Final Rejection | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA |
| 17231273 | COMPOSITIONS AND METHODS FOR TREATING CANCER | Non-Final OA | Battelle Memorial Institute |
| 18728706 | COMPOSITION, METHOD FOR MICROORGANISM GROWTH SUPPRESSION IN COMPOSITION FOR ORAL USE, AND AGENT FOR POTENTIATION OF MICROORGANISM-GROWTH-SUPPRESSING EFFECT OF QUERCETIN OR GLYCOSIDE THEREOF | Non-Final OA | SUNTORY HOLDINGS LIMITED |
| 18724520 | METHODS OF TREATING, AMELIORATING, AND/OR PREVENTING STRESS-RELATED DISORDER | Non-Final OA | Yale University |
| 18006584 | USE OF 2,3,5-SUBSTITUTED THIOPHENE COMPOUND FOR PREVENTING, ALLEVIATION, OR TREATING MASTOCYTOSIS | Non-Final OA | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY |
| 17794823 | NOVEL COMPOUND AND USE THEREOF | Final Rejection | THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION |
| 18376308 | DISINFECTING COMPOSITION, APPLICATOR, AND METHOD OF DISINFECTING | Non-Final OA | Medline Industries, LP |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy